The Genesis of MTII – Tantra

The research that underpins Tantra’s MTII began over 30 years ago in the US. At that time the dramatic increase in incidence of skin cancer and its impacts were beginning to be discovered and new solutions sought. The National Cancer Institute (NCI) sponsored researchers to explore applications for various peptides as part of its melanoma prevention strategy.

This study led them to investigate peptides that acted on melanocyte receptors. The rationale behind this being that increased melanin leads to more efficient photoprotection, as melanin is a highly successful and naturally occurring UV quencher and filter. By consistently increasing melanin in the skin, skin damage from light and UV radiation can be lessened.

A synthetic analogue of the naturally occurring alpha melanocyte stimulating hormone (-MSH) was modified to increase binding affinity to its main receptor MC1R. Altered slightly, Tantra’s MTII  lasts slightly longer in the skin and delivers a prolonged result.

Above all stands our goal of becoming a truly green research and marketing company by continuing to build our knowledge concerning light, UV, skin and health in an age when the realities of climate change are beginning to be realized and the full benefits of medicinal photoprotection are becoming more and more apparent.